Synaffix BV products

Enabling immune cell engagers & other protein conjugates.

GlycoConnect™ replaces the existing antibody glycan with a therapeutic payload. Synaffix has established a simple, yet powerful, clinical-stage platform technology enabling best-in-class ADCs, bispecific antibodies and the targeted delivery of various other therapeutic payloads, all without modifying the antibody sequence.

Any antibody can be converted into a stably conjugated ADC in just a few days by modifying the native antibody glycan using our highly efficient enzymes and metal-free click chemistry approach. Multiple independent experiments confirm that the native glycan position is likely one of the best for attaching ADC payloads to antibodies.